PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, supported by a new investment group including a private equity fund advised by Kew Capital LLP and Phoenix IP Ventures-III, LLC, will continue to market its well established branded products Aldomet® (methyldopa), Indocin® (indomethacin) and the Canadian rights for the antibiotic Vancocin® (vancomycin hydrochloride). In addition, the Company will focus significant new investments into its advanced pipeline of pain management products. The Company is planning to make strategic investments to grow its core business, including expanding use, gaining approval in additional countries and/or acquiring new assets.
